| Home Market Dynamics Sector Analysis Company Insights AI Investing Strategies Contact Us Login |
| Gilead Sciences is advancing significantly in Product/Service Development, particularly in its HIV prevention strategies and innovative treatment approaches. The company's efforts in HIV prevention initiatives, including the delivery of lenacapavir and long-acting treatments, contribute to its growth and leadership in the sector. Coupled with its successful HIV portfolio, Gilead is well-positioned for future growth. However, the focus on relatively novel therapies such as personalized cell therapy for diseases like Parkinson's may present challenges in market acceptance. |
| The price action of Gilead Sciences (GILD) is impacted by broad market risk appetite, sector price trend, company-specific performance and market structure. The trend sentiment at 1 is bullish. The market sentiment at 1.1 is very bullish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next.GILD is likely to move up since both trend sentiment and market sentiment are positive. The positive sentiment force for sector is at 1.1, and the negative at 0 on 2025-11-21. The forces of Sentiment towards Fundamentals (2.1), Valuation Sentiment (1.8), Market Risk Appetite (1), Sector Price Trend (1), Stock Price Trend (1), Option Sentiment (0), and Price Level Sentiment (0) will drive up the price. The forces of and Price Level Sentiment (0) will drive down the price. The sentiment for Sector Price Trend is calculated based on the price trend of related sector ETF. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Appetite is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
| GILD | |||||||||||||
| Date | Attention | Price | Price Level | Change | SMA10 Trend | Trend Sentiment | Hourly Trend | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-21 | 0%(0%) | 1 | 0.25% | 1.1 | 2.1 | -1 | |||||||
| 2025-11-20 | 0%(0%) | 1 | 0.25% | 0.7 | 1.9 | -1 | |||||||
| 2025-11-19 | 0%(0%) | 1 | 0.25% | 0.7 | 2.2 | -1 | |||||||
| 2025-11-18 | 0%(0%) | 1 | 0.25% | 0.5 | 2.1 | -1 | |||||||
| 2025-11-17 | 0%(0%) | 1 | 0.25% | 0.4 | 1.6 | -1 | |||||||
| 2025-11-16 | 0%(0%) | 1 | 0.25% | 0.5 | 1.2 | -1 | |||||||
| 2025-11-15 | 0%(0%) | 1 | 0.25% | 0.5 | 1.2 | -1 | |||||||
| 2025-11-14 | 0%(0%) | 1 | 0.25% | 0.5 | 1.4 | -1 | |||||||
| 2025-11-13 | 0%(0%) | 1 | 0.25% | 0.3 | 0.3 | 6 | |||||||
| 2025-11-12 | 0%(0%) | 1 | 0.25% | 0.1 | -0.9 | -1 | |||||||
| Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | |||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | |||||||||||||
| 2025-11-21 17:10:41 While Gilead's HIV division thrives, its oncology and immunology segments face challenges that could impact overall earnings. |
| 2025-11-21 17:10:41 Gilead's stock demonstrated an increase, indicating positive market sentiment and investor confidence. |
| 2025-11-21 17:10:41 Recent strategic M&A activities signal potential growth in Gilead's pipeline, particularly in the oncology sector. |
| 2025-11-21 17:10:41 Analyst expectations have improved following Gilead's strong Q3 results, showcasing confidence in its future performance and advancements in its HIV division. |
| 2025-11-21 17:10:41 Gilead Sciences' strong performance in the HIV sector, particularly through its leading products like Biktarvy and new launches, positions the company for sustained growth. |